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Abstract
Background:  Co-morbidities of vertiginous diseases have so far not been investigated
systematically. Thus, it is still unclear whether the different vertigo syndromes (e.g. benign
paroxysmal positional vertigo (BPPV), Meniere's disease (MD), vestibular migraine and phobic
vertigo (PPV)) have also different spectrums of co-morbidities.
Methods: All patients from a cohort of 131 participants were surveyed using a standardised
questionnaire about the co-morbidities hypertension, diabetes mellitus, BMI (body mass index),
migraine, other headache, and psychiatric diseases in general and the likelihood of a depression in
particular.
Results: We noted hypertension in 29.0% of the cohort, diabetes mellitus in 6.1%, migraine in
8.4%, other headache in 32.1%, psychiatric diseases in 16.0%, overweight and obesity in 33.6% and
13.7% respectively, as well as a clinical indication for depression in 15.9%.
Conclusion: In general, we did not detect an increased prevalence of the co-morbidities diabetes
mellitus, arterial hypertension, migraine, other headache and obesity compared to the general
population. There was an increased prevalence of psychiatric co-morbidity in patients with PPV,
and the prevalence of hypertension was elevated in patients with MD.
Background
Vertigo and dizziness are, after headache and back pain,
the most common symptoms in daily clinical practice.
The prevalence of vertigo is age depending and is in the
range within 17 and 39% [1]. Vertigo is frequently noted
as symptoms of other neurological, cardiovascular, hae-
matological, and infectious diseases, and as adverse reac-
tions to medical treatment. Otherwise it is not always easy
to differentiate if these diseases are the cause of vertigo
syndrome or to be seen as a co-morbidity of the vertigo
syndrome. It is also not known that these co-morbidities
have an influence on the prognosis of the main disorder.
The aim of our study was to detect co-morbidities in ver-
tiginous diseases in general and in a subgroup with clearly
defined vertigo syndromes in particular. Therefore we
analysed a sample of our patients who were seen in our
outpatient clinic. The outpatient clinic is a tertiary centre
for patients with vertigo and dizziness. In the majority of
cases these patients suffer from chronic vertigo and pre-
sented themselves after several consultations with medical
specialists per referral at our outpatient clinic. Some of the
most frequent vertiginous diseases diagnosed in our out-
patient clinic [2] were examined in detail: postural phobic
vertigo (PPV), benign paroxysmal positional vertigo
(BPPV), Meniere's disease (MD) and vestibular migraine
(VM).
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Methods
Study design
This cohort study was conducted at the Department of
Neurology, Ludwig-Maximilians-Universität Munich in
the period from 2003 to 2007. A total of 193 patients were
seen and 131 of these patients were included, the remain-
ing 62 patients were excluded because of missing data
respectively questionnaires or missing consent to our
study. All included participants gave their written
informed consent to this observational study. All data
were anonymised.
Each patient, who kept an appointment in the vertigo out-
patient clinic of the Department of Neurology Munich,
received a standardised questionnaire [additional file 1],
which contained, among other issues, questions about co-
morbidities arranged according to physiological systems.
This information from the patients was compared with
their medical history and with the results of the clinical
examination on the same day. In our analysis, we limited
the range of co-morbidities to the more common diseases
arterial hypertension and diabetes mellitus, variations of
the body mass index [3], migraine and other headache, as
well as psychiatric diseases in general and depression in
particular, the latter evaluated by the ADS-L-Score [4].
ADS-L is the common depression scale long version. It is
a test that contains 20 questions used to discover a clinical
relevant depression [additional file 1].
Inclusion criteria
We only included patients who were diagnosed with a ver-
tiginous disease of vestibular (central or peripheral) or
psychogenic origin, and who were seen by an experienced
investigator in our department.
Ethical approval
In order to get detailed and structured information about
the history of the patients and the signs of the actual clin-
ical symptoms we asked the patients to fill in a structured
questionnaire, which was signed by each patient. Beside
the questionnaire the patients were also interviewed by an
experienced neurologist who was also responsible for the
documentation of the results of further technical investi-
gations. Since the study was not experimental and the data
were gained in clinical routine, the approval of an ethics
committee was not necessary.
Statistics
The statistical analysis was done with SPSS 14.0 and 15.0
for Windows XP. P-values for the association of main
diagnoses and co-morbidities were calculated using
Fisher's exact test.
Results
In total, 131 patients corresponded to the criteria of our
trial and completed the questionnaire. The mean age was
54.0 years, 57.3% were female. Fifty-three patients
(40.5%) in this cohort were diagnosed with PPV, 19
patients (14.5%) had BPPV, 11 patients (8.4%) had MD
and 14 patients (10.7%) were classified as VM.
With regard to the co-morbidities arterial hypertension,
diabetes mellitus, headache, migraine, and psychiatric
diseases reported by the patients, we noted one co-mor-
bidity in 49 patients (37.4%), two co-morbidities in 27
patients (20.6%) and three co-morbidities in eight
patients (6.1%) of the cohort.
Arterial hypertension
We noted hypertension in 38 patients (29.0%). There was
a similar prevalence in PPV (26.4%) and in VM (28.6%).
A considerably higher prevalence of hypertension was
detected in patients with MD (63.3%, p = 0.014) and a
considerably lower prevalence in patients with BPPV
(15.8%, p = 0.27) [table 1].
Diabetes mellitus
The prevalence of diabetes mellitus in our cohort reached
6.1%. There was a marginal higher prevalence in patients
with MD (18.2%, p = 0.13) [table 1].
Table 1: Main co-morbidities (1 smaller denominator, since VM patients were excluded)
diagnosis Hypertension Diabetes mellitus Migraine Other forms of headache Psychiatric diseases
n%n % n % n % n %
PPV (n = 53) 14 26.4 4 7.6 4 7.6 22 41.5 14 26.4
BPPV (n = 19) 3 15.8 1 5.3 3 15.8 5 26.3 2 10.5
MD (n = 11) 7 63.6 2 18.2 1 9.1 2 18.2 0 0.0
VM (n = 14) 4 28.6 0 0.0 - - 8 57.1 2 14.3
Cohort (n = 131) 38 29.0 8 6.1 11 9.41 48 36.6 21 16.0BMC Neurology 2009, 9:29 http://www.biomedcentral.com/1471-2377/9/29
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Headache
Eleven patients (9.4%), patients with VM were not
included, suffered from migraine. Exceeding one third of
the patients (36.6%) suffered from another form of head-
ache. There was a slightly but not significantly higher
prevalence of other headache amongst the patients with
PPV (relative risk 1.25, p = 0.36) [table 1].
Psychiatric disorders
Compared to the rest of the cohort, a 2.9-fold prevalence
of psychiatric disorders (p = 0.014) was a feature of PPV
(26.4%). The ADS-L test for depression [4] produced 113
valid scores (86.3%) with a mean value of 19.2 and a
standard deviation of s = 10.84. There was a low likeli-
hood of depression in 43.4% of the patients, a moderate
likelihood in 27.4%, and a high likelihood in 12.4%.
16.8% of the patients scored 30 points or more, giving a
clinical indication of a depression [table 1].
Body mass index (BMI)
Approximately half of the patients (49.6%) were diag-
nosed as being within the normal weight range and 33.6%
were diagnosed as overweight. The criteria for obesity
were achieved by 13.7% of the patients. The mean ±
standard deviation of the BMI was 25.52 ± 4.26 [table 2].
Depression (ADS-L-score)
Based on the inclusion-criteria of the ADS-L [4], there
were the following percentages and mean values of valid
scores in the main diagnoses: PPV (88.7%, 20.64), BPPV
(89.5%, 17.18), MD (72.7%, 19.75), VM (100%, 20.00).
In patients with PPV, we found a score of 30 points or
higher in 19.2%, which can be viewed as a strong clinical
indication for a manifest depression. Compared with this,
21.4% of patients with VM, 12.5% of those with MD, and
11.8% of patients with BPPV achieved a score of 30 points
or more. Patients with PPV had a relative risk of 1.26 (p =
0.62) and patients with VM had a relative risk of 1.32 (p =
0.70) for a clinical probable depression compared to the
rest of the cohort [additional file 2, tables 3 and 4].
Patients, not included in the analysis
62 of 193 patients were not included in our study because
of missing data, missing questionnaires or missing con-
sent. The average age of these patients was 57.7 years
(cohort 54.0 years) and the prevalence of co-morbidities
obtained almost similar values as the prevalence of
comorbidities in the cohort [table 5].
Discussion
The aim of our study was the evaluation of co-morbidities
in a group of patients with vertiginous diseases. We did
not investigate the prevalence of the different vertiginous
diseases in the general population since we included only
patients screened in our specialized outpatient clinic. We
made sure that the patients who were not included in the
study due to missing data had nearly the same mixture of
diagnosis as the study population. It is therefore unlikely
that this biased the seen co-morbidities.
In comparison to the data of a national telephone health
survey in Germany [5], the prevalence of hypertension in
our cohort (29.0%) reached a marginally higher percent-
age than in the general population (27.1%). From this, we
can infer that there was no distinctive feature in the prev-
alence of hypertension in patients with a vertiginous dis-
ease in our study. In comparison to other studies with
vertigo patients, we could not find a relationship between
BPPV and hypertension [6], which may be due to a lack of
statistical power in this subgroup.
The prevalence of diabetes mellitus in Germany is approx-
imately 5% to 7% of the general population [7]; we
detected a similar prevalence in our trial (6.1%). Moreo-
ver, with a prevalence of 6.1% in our trial, we confirmed
the findings of a previous study [8] that there is no ele-
vated co-morbidity of diabetes mellitus and a vertiginous
disease, especially if we consider that the patients in the
study were on average older than the general population Table 2: Body mass index (BMI)
BMI n %
< 18.5 (underweight) 1 0.8
18.5 to < 25 (normal weight) 65 49.6
25 to < 30 (overweight) 44 33.6
> 30 (obesity) 18 13.7
missing 3 2.3
total 131 100.0
Table 3: ADS-L (cohort)
points score n %
0 – 16 (low likelihood) 49 43.4
17 – 22 (moderate likelihood) 31 27.4
23 – 29 (high likelihood) 14 12.4
30 and above (clinical indication) 19 16.8
total 113 100.0BMC Neurology 2009, 9:29 http://www.biomedcentral.com/1471-2377/9/29
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and that the prevalence of diabetes is strongly dependent
on age. The median age in our cohort diagnosed with ver-
tigo was 54.0 years and therefore slightly higher than in
the population-based survey explaining the small differ-
ences in prevalence of diabetes mellitus.
Comparative data from a national survey [9] indicated
that in the age group 50 to 59 years, 40.2% were over-
weight and 23.0% were obese. In contrast, 33.6% of the
patients in our study were overweight and only 13.7%
were obese. Furthermore, we did not find elevated preva-
lences of obesity and higher BMI among this cohort of ver-
tigo patients, in contrast to previously published results
on the prevalence of chronic headache and BMI [10].
Based on the data of a national survey [11], the prevalence
of any headache is approximately 69% in women and
53% in men. The prevalence of headache (except
migraine) in our study was 36.6% and therefore signifi-
cantly lower than in the general population. The patients
with PPV showed a marginally (relative risk: 1.25) but not
significantly higher prevalence of headaches than the
other patients from the cohort.
For the whole sample of patients with vertigo there was no
increased prevalence of migraine in our study (9.4%)
compared to a recent epidemiological study that observed
a 6-month prevalence of 11.2% for migraine [12]. We
excluded the patients with VM from this analysis since per
definition the prevalence of migraine in these patients has
to be 100%.
The most interesting finding was concerning the preva-
lence of psychiatric diseases assed with the ADS-L ques-
tionnaire, an evaluated and often used questionnaire. We
found a significantly increased prevalence of psychiatric
diseases in patients with PPV (p = 0.014) compared to the
other main diagnoses. In comparing the prevalence in co-
morbidities, we included all psychiatric disorders from
the ICD-10 Chapter V (F) including depression. Not every
patient with PPV suffered from other psychiatric disor-
ders, supporting the concept of PPV as a separate entity
and not only as a symptom of a more general psychiatric
disorder. However, the assumed prevalence of psychiatric
disorders in patients with PPV was in line with the one-
year-prevalence of psychiatric diseases in Europe [13]. In
comparison, a study about the prevalence of affective dis-
eases in upper Bavaria revealed only a prevalence of 6.8%
for affective diseases like depression [14].
Furthermore, 19.2% of the patients with PPV and more
than 10% of the patients with BPPV and MD and 21.4%
of the patients with VM scored 30 points or more in the
ADS-L, which indicates a strong clinical suspicion of a
manifest depression. The group of PPV patients and the
patients with VM had a slightly but not significantly
Table 4: ADS-L (main diagnoses)
points score 0 – 16
(low likelihood)
17 – 22
(moderate likelihood)
23 – 29
(high likelihood)
30 and above
(clinical indication)
N% N % N % N %
PPV 16 34.0 17 36.2 5 10.6 9 19.2
BPPV 10 58.8 1 5.9 4 23.5 2 11.8
MD 3 37.5 4 50.0 0 0.0 1 12.5
VM 5 35.7 5 35.7 1 7.1 3 21.4
Table 5: diagnoses and co-morbidities of patients not included in the analysis
diagnosis n % co-morbidities n %
BPPV 12 16.1 hypertension 20 32.2
vertigo with psychogenic origin 12 16.1 diabetes mellitus 6 9.7
MD 8 12.9 migraine 5 8.1
Vestibular paroxysmia 3 4.8 psychiatric diseases 11 17.8
orthostatic vertigo 3 4.8
VM 2 3.2
multifactorial vertigo 2 3.2
tension-type headache 2 3.2
cerebellar syndrome 2 3.2
other vertigo 9 14.5
vertigo of unclear origin 7 11.3
total 62 100.0BMC Neurology 2009, 9:29 http://www.biomedcentral.com/1471-2377/9/29
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increased relative risk (1.26 and 1.32) of suffering from a
manifest depression. Referring to this we cannot rule out
a connection between depression and chronic vertigo and
vice versa. With respect to data of another vertigo trial
[15], our cohort showed approximately the same preva-
lence for a clinical relevant depression. In contrast, the
prevalence of depression in our study cohort was signifi-
cantly lower than in trials with patients suffering from ten-
sion-type headache [16,17] and migraine [16,18]. In a
comparative study with patients diagnosed with diabetes
mellitus, 22.0% scored 16 or more in the CES-D [19].
Another study, which evaluated the outcome 100 days
after an ischemic stroke, showed a CES-D-cut-off for
depression (10 points) in 32.9% [20], equivalent to a
score of 20 points or more in the ADS-L, which 40.7% of
the patients in our study achieved. In contrast, a study
with patients suffering from chronic pain, reported an
average CES-D of 24.0, which exceeds the average score of
19.2 in our study [21]. The prevalence of depression in
vertigo is comparable to the prevalence of depression in
other chronic diseases.
Limitations of the study are that due to the number of
cases the study did not allow for an analysis stratified by
gender and age. It further should be mentioned that the
participants in our study are patients from a tertiary centre
specializing in vertiginous disease, which is likely to result
in an over- or underrepresentation of certain vertiginous
diseases (e.g. higher prevalence of PPV) and we therefore
limited our analysis on the examination of the co-morbid-
ities in vertiginous diseases.
Conclusion
In conclusion, we found a higher prevalence of psychiatric
co-morbidities, such as depression in the PPV patients, as
well as a higher prevalence of hypertension in patients
with MD. Otherwise there was no elevated prevalence of
hypertension, diabetes mellitus, general headaches and
migraine as well as obesity in comparison to general pop-
ulation. Further studies with larger numbers of patients
need to be performed to give additional support to our
findings.
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